New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
07:23 EDTARIAConcerns about ARIAD overblown, says RBC Capital
RBC Capital believes that key investor concerns about thrombotic arterial events and hypertension linked to ARIAD's Iclusig are overblown. The firm doesn't expect adverse events raised by a study of the drug to significantly affect the drug's launch or an upcoming Phase III study. RBC Capital maintains an Outperform rating on the stock.
News For ARIA From The Last 14 Days
Check below for free stories on ARIA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
12:37 EDTARIASarissa says ARIAD denied 'poison pill' waiver request
Subscribe for More Information
August 25, 2014
12:37 EDTARIAARIAD ICLUSIG prescriptions encouraging, says BMO Capital
Subscribe for More Information
10:40 EDTARIABiotechs rise after InterMune acquired by Roche
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use